Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Erythroderma

INTRODUCTION

Erythroderma (literally, "red skin"), also sometimes called exfoliative dermatitis, is a severe and potentially life-threatening condition that presents with diffuse erythema and scaling involving all or most of the skin surface area (≥90 percent, in the most common definition). Erythroderma is the clinical presentation of a wide range of cutaneous and systemic diseases (including psoriasis and atopic dermatitis), drug hypersensitivity reactions, and more rarely Sézary syndrome, a leukemic subtype of cutaneous T-cell lymphoma.

This topic will discuss the clinical manifestations, diagnosis, and treatment of erythroderma. Sézary syndrome is discussed separately. (See "Clinical presentation, pathologic features, and diagnosis of Sézary syndrome".)

EPIDEMIOLOGY

Erythroderma is a rare condition. The annual incidence has been estimated to be approximately 1 per 100,000 in the adult population [1]. In a retrospective study, erythroderma accounted for 13 in 100,000 patients presenting with skin diseases in China [2]. Erythroderma can occur at any age and in both sexes, but is more frequent in older adults (mean age 42 to 61 years) and in males [2-6]. Erythroderma is exceedingly rare in children; its prevalence is estimated to be approximately 0.1 percent in pediatric dermatology clinic populations [7,8].

ETIOLOGY

Cutaneous and systemic conditions — A wide range of cutaneous or systemic diseases can evolve to or cause erythroderma (table 1).

Exacerbation of a preexisting inflammatory dermatosis – The most common cause of erythroderma is the exacerbation of a preexisting inflammatory dermatosis, most often psoriasis or atopic dermatitis [3-6]. In patients with psoriasis, triggers of erythroderma include the abrupt discontinuation of systemic corticosteroids or other immunosuppressant therapy, systemic illnesses, phototherapy burns, medications (eg, lithium, antimalarials), or HIV infection [9].

                         

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Apr 22, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Sigurdsson V, Steegmans PH, van Vloten WA. The incidence of erythroderma: a survey among all dermatologists in The Netherlands. J Am Acad Dermatol 2001; 45:675.
  2. Li J, Zheng HY. Erythroderma: a clinical and prognostic study. Dermatology 2012; 225:154.
  3. Pal S, Haroon TS. Erythroderma: a clinico-etiologic study of 90 cases. Int J Dermatol 1998; 37:104.
  4. Akhyani M, Ghodsi ZS, Toosi S, Dabbaghian H. Erythroderma: a clinical study of 97 cases. BMC Dermatol 2005; 5:5.
  5. Rym BM, Mourad M, Bechir Z, et al. Erythroderma in adults: a report of 80 cases. Int J Dermatol 2005; 44:731.
  6. Sigurdsson V, Toonstra J, Hezemans-Boer M, van Vloten WA. Erythroderma. A clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Acad Dermatol 1996; 35:53.
  7. Sarkar R, Garg VK. Erythroderma in children. Indian J Dermatol Venereol Leprol 2010; 76:341.
  8. Sarkar R, Basu S, Sharma RC. Neonatal and infantile erythrodermas. Arch Dermatol 2001; 137:822.
  9. Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the "red man". Clin Dermatol 2005; 23:206.
  10. Sheen YS, Chu CY, Wang SH, Tsai TF. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan. J Dermatolog Treat 2009; 20:340.
  11. Sigurdsson V, Toonstra J, van Vloten WA. Idiopathic erythroderma: a follow-up study of 28 patients. Dermatology 1997; 194:98.
  12. Thestrup-Pedersen K, Halkier-Sørensen L, Søgaard H, Zachariae H. The red man syndrome. Exfoliative dermatitis of unknown etiology: a description and follow-up of 38 patients. J Am Acad Dermatol 1988; 18:1307.
  13. Groves RW, Kapahi P, Barker JN, et al. Detection of circulating adhesion molecules in erythrodermic skin disease. J Am Acad Dermatol 1995; 32:32.
  14. Sigurdsson V, de Vries IJ, Toonstra J, et al. Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endothelium in situ in patients with erythroderma, mycosis fungoides and atopic dermatitis. J Cutan Pathol 2000; 27:436.
  15. Sigurdsson V, Toonstra J, Bihari IC, et al. Interleukin 4 and interferon-gamma expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An immuno-histochemical study. J Cutan Pathol 2000; 27:429.
  16. Kanthraj GR, Srinivas CR, Devi PU, et al. Quantitative estimation and recommendations for supplementation of protein lost through scaling in exfoliative dermatitis. Int J Dermatol 1999; 38:91.
  17. Green MS, Prystowsky JH, Cohen SR, et al. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996; 34:911.
  18. Jaffe D, May LP, Sanchez M, Moy J. Staphylococcal sepsis in HIV antibody seropositive psoriasis patients. J Am Acad Dermatol 1991; 24:970.
  19. Bakri FG, Al-Hommos NA, Shehabi A, et al. Persistent bacteraemia due to methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in a patient with erythrodermic psoriasis. Scand J Infect Dis 2007; 39:457.
  20. Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 2008; 159:105.
  21. Garg G, Thami GP. Psoriasis Herpeticum due to Varicella Zoster Virus: A Kaposi's Varicelliform Eruption in Erythrodermic Psoriasis. Indian J Dermatol 2012; 57:213.
  22. Santmyire-Rosenberger BR, Nigra TP. Psoriasis herpeticum: three cases of Kaposi's varicelliform eruption in psoriasis. J Am Acad Dermatol 2005; 53:52.
  23. Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol 1980; 5:105.
  24. Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol 2010; 11:157.
  25. Suzuki M, Oki T, Sugiyama T, et al. Muscarinic and alpha 1-adrenergic receptor binding characteristics of saw palmetto extract in rat lower urinary tract. Urology 2007; 69:1216.
  26. Bi MY, Curry JL, Christiano AM, et al. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 2011; 64:53.
  27. Ram-Wolff C, Martin-Garcia N, Bensussan A, et al. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies. Am J Dermatopathol 2010; 32:755.
  28. Zip C, Murray S, Walsh NM. The specificity of histopathology in erythroderma. J Cutan Pathol 1993; 20:393.
  29. Vasconcellos C, Domingues PP, Aoki V, et al. Erythroderma: analysis of 247 cases. Rev Saude Publica 1995; 29:177.
  30. Nagler AR, Samimi S, Schaffer A, et al. Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome. J Am Acad Dermatol 2012; 66:503.
  31. Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62:655.
  32. Viguier M, Pagès C, Aubin F, et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol 2012; 167:417.
  33. Khaled A, Sellami A, Fazaa B, et al. Acquired erythroderma in adults: a clinical and prognostic study. J Eur Acad Dermatol Venereol 2010; 24:781.
  34. Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989; 21:985.
  35. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995; 131:1003.
  36. Kubica AW, Davis MD, Weaver AL, et al. Sézary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol 2012; 67:1189.